Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial

Masatoshi Kudo; Etsuro Hatano; Shinichi Ohkawa; Hirofumi Fujii; Akihide Masumoto; Junji Furuse; Yoshiyuki Wada; Hiroshi Ishii; Shuntaro Obi; Shuichi Kaneko; Seiji Kawazoe; Osamu Yokosuka; Masafumi Ikeda; Katsuaki Ukai; Sojiro Morita; Akihito Tsuji; Toshihiro Kudo; Mitsuo Shimada; Yukio Osaki; Ryosuke Tateishi; Gen Sugiyama; Paolo Abada; Ling Yang; Takuji Okusaka; Andrew X. Zhu

doi:10.1007/s00535-016-1247-4

Related publications

Article2015

Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trial

Shinichi Ohkawa, Takuji Okusaka, Masatoshi Kudo, Etsuro Hatano, Hirofumi Fujii, Akihide Masumoto, Junji Furuse, Yoshiyuki Wada, Hiroshi Ishii, Shuntaro Obi, Kuniaki Arai, Seiji Kawazoe, Osamu Yokosuka, Masafumi Ikeda, Katsuaki Ukai, Sojiro Morita, Hiroya Asou, Paolo Abada, Lingwei Yang, Andrew X. Zhu

Article2016

Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma

Andrew X. Zhu, Ari David Baron, Peter Malfertheiner, Masatoshi Kudo, Seiji Kawazoe, Denis Pezet, Florian Weißinger, Giovanni Brandi, Carlo Barone, Takuji Okusaka, Yoshiyuki Wada, Joon Oh Park, Baek‐Yeol Ryoo, Y. Choi, Hyun Cheol Chung, Chung‐Pin Li, Chia-Jui Yen, Kuan‐Der Lee, Shao-Chun Chang, Ling Yang, Paolo Abada, Ian Chau

Article2016

Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade

J.-F. Blanc, Stephen L. Chan, J.O. Park, Baek‐Yeol Ryoo, Chung‐Jen Yen, Masatoshi Kudo, Rtp Poon, Davide Pastorelli, Ari David Baron, Tatiana Pfiffer, Takuji Okusaka, Kateřina Kubáčková, Jörg Trojan, Javier Sastre, Ian Chau, Paolo Abada, Samuel Chang, Ling Yang, Alice Zhu

Article2020

Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial

Masatoshi Kudo, Takuji Okusaka, Kenta Motomura, Izumi Ohno, Manabu Morimoto, Satoru Seo, Yoshiyuki Wada, Shinpei Sato, Tatsuya Yamashita, Masayuki Furukawa, Takeshi Aramaki, Seijin Nadano, Kazuyoshi Ohkawa, Hirofumi Fujii, Toshihiro Kudo, Junji Furuse, Hiroki Takai, Gosuke Homma, Reigetsu Yoshikawa, Andrew X. Zhu

Article2016

Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis

Joon Oh Park, Baek‐Yeol Ryoo, Chia-Jui Yen, Masatoshi Kudo, Ling Yang, Paolo Abada, Rebecca Cheng, Mauro Orlando, Andrew X. Zhu, Takuji Okusaka

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial

Discussion(0)

Related publications

Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trial

Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma

Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade

Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial

Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis